(As of December 12, 2025 | Post Q3 2025 earnings and recent insider transactions)
Current market capitalization: ≈ $213 billion (based on ~$121.25/share and 1.74 billion shares outstanding)
Introduction
Abbott Laboratories (NYSE: ABT), founded in 1888 by Wallace Calvin Abbott in Chicago, Illinois, is a diversified global healthcare company specializing in medical devices (e.g., FreeStyle Libre glucose monitors), diagnostics (e.g., Alinity systems), nutritionals (e.g., Ensure, Similac), and established pharmaceuticals. Headquartered in Abbott Park, Illinois, it operates in 160+ countries with ~114,000 employees. Public since 1929, its ownership is highly diffuse and institutionally dominated (~81%), with insiders ~0.54% and retail ~21.52%. No single entity holds majority control, promoting broad accountability. The table below details the top 10 shareholders from Q3 2025 13F filings and SEC data, with values at current market cap. Recent activity includes minor insider sales (~$1.34M in Nov 2025) and $5B quarterly buybacks reducing shares by ~0.5% YoQ.
| Rank | Owner / Stakeholder | Ownership % | Approx. Value ($213B valuation) | Detailed Notes |
|---|---|---|---|---|
| 1 | Vanguard Group Inc. | 9.96% | $21.2 billion | Largest holder via index funds (e.g., VTI, VOO); owns ~173.15M shares as of Sep 30, 2025. Passive with ~$9.3T AUM; added ~0.3% YoY; core S&P 500 weighting (~6%). No direct control; focuses on diagnostics/devices growth. |
| 2 | BlackRock Inc. | 8.14% | $17.3 billion | Holds ~141.56M shares through iShares ETFs (e.g., IVV); passive/active mix. Increased ~0.5% in Q3 2025; board observer on governance/ESG. Key in healthcare funds; ABT ~0.3% of portfolio. |
| 3 | State Street Corporation | 4.50% | $9.6 billion | Owns ~78.23M shares via SPDRs (e.g., SPY); fully passive. Stable QoQ; votes proxies on exec comp and drug pricing ethics. ~4% of health holdings; supports $20B annual buybacks. |
| 4 | Capital International Investors | 3.54% | $7.5 billion | ~61.61M shares in growth strategies; active manager. Added ~18% in Q3 2025; focuses on nutritionals (up 4.2% Q3 YoY). |
| 5 | JPMorgan Chase & Co. | 3.38% | $7.2 billion | ~58.77M shares across asset management; index/active blend. Up ~1% in 2025; provides banking/debt for ABT's $10B+ cash reserves. |
| 6 | Geode Capital Management, LLC | 2.41% | $5.1 billion | Fidelity affiliate with ~42M shares in index trackers; passive. Grew ~0.3% in Q3; tracks S&P 500; minimal voting power. |
| 7 | Morgan Stanley | 2.20% | $4.7 billion | ~38.3M shares via wealth/ETFs; active in advisory. Stable QoQ; engages on shareholder proposals re: antitrust. |
| 8 | Capital Research Global Investors | 2.00% | $4.3 billion | ~34.8M shares; active manager. Added ~5% in Q3; holds for medical devices (up 12.5% Q3 organic). |
| 9 | Bank of America Corp /DE/ | 1.80% | $3.8 billion | ~31.3M shares; strategic peer holding. Increased ~0.5% QoQ; synergies in healthcare financing. |
| 10 | Robert B. Ford (CEO) | 0.02% | $43 million | ~350K shares; largest active insider. Recent stability; oversees strategy since 2020; aligns with $5.12-5.18 FY2025 adj. EPS guidance. |
Total Top 10 = ~47.44% | Remaining: Other Institutions (~34%), Other Insiders (~0.52%, e.g., Robert E. Funck CFO at ~0.005%), Retail (~21.52%) | Grand Total = 100%
Conclusion
As of December 2025, Abbott Laboratories' ownership is institutionally led (~81% total) by passive titans like Vanguard and BlackRock, ensuring stability for its $11.37B Q3 2025 revenue (up 6.9% YoY, organic 7.5% excluding COVID) and $1.64B net income (GAAP EPS $0.94, adj. $1.30), with FY2025 guidance reaffirmed at 7.5-8.0% organic growth and $5.12-5.18 adj. EPS (double-digit at midpoint). Insiders (~0.54% combined) like Ford provide continuity amid expansions (e.g., TriClip approval in Japan), while retail's ~21.52% stake reflects healthcare appeal. With $213B market cap (up ~9% YoY) and $20B buybacks authorized, expect ~0.5% annual share reductions, minor institutional rebalancing in Q4 13Fs (due Feb 2026), and Q4 revenue ~$11.4B. This structure supports diagnostics dominance via $2.20 annual dividends (1.8% yield). For filings, visit SEC EDGAR or Abbott's investor relations.